Tue, May 25, 2010
Mon, May 24, 2010
Fri, May 21, 2010
Thu, May 20, 2010
Wed, May 19, 2010
Tue, May 18, 2010
Mon, May 17, 2010
Sun, May 16, 2010
Sat, May 15, 2010
Fri, May 14, 2010
Thu, May 13, 2010
Wed, May 12, 2010
[ Wed, May 12th 2010 ] - Market Wire
ENVIROTEK Becomes "SUFFER"
Tue, May 11, 2010

Targacept Announces Participation in Upcoming Conferences


//health-fitness.news-articles.net/content/2010/ .. unces-participation-in-upcoming-conferences.html
Published in Health and Fitness on Tuesday, May 18th 2010 at 6:00 GMT by Market Wire   Print publication without navigation


WINSTON-SALEM, N.C.--([ BUSINESS WIRE ])--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that Alan A. Musso, Senior Vice President, Finance and Administration and Chief Financial Officer, is scheduled to present at the following conferences:

  • Citi 2010 Global Health Care Conference at the Hilton New York Hotel in New York on Wednesday, May 25, 2010 at 2:00 p.m. Eastern Daylight Time; and
  • 9th Annual Needham Healthcare Conference at the New York Palace Hotel in New York on Wednesday, June 9, 2010 at 9:20 a.m. Eastern Daylight Time.

Each presentation will be audio webcast and accessible from the Investor Relations page of Targacepta™s website, [ www.targacept.com ]. To ensure a timely connection to either webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of each audio presentation will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacepta™s website for at least two weeks following the corresponding event.

About Targacept

Targacept is a clinical-stage biopharmaceutical company with a vision of building health and restoring independence for patients. Targacept has leveraged its leadership position in NNR research to build a diverse pipeline of NNR Therapeutics(TM) in development to treat an array of central nervous system diseases and disorders, including major depressive disorder, attention deficit/hyperactivity disorder, Alzheimera™s disease and cognitive dysfunction in schizophrenia. In addition, Targacept has alliances with the global pharmaceutical companies AstraZeneca and GlaxoSmithKline. Targacepta™s news releases are available on its website at [ www.targacept.com ].


Publication Contributing Sources